Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 ...
Bright Minds Biosciences initiates BREAKTHROUGH Study, a Phase 2 trial evaluating BMB-101, a 5-HT2C agonist, for drug-resistant epilepsy. The trial targets 20 adult participants with Absence Epilepsy or Developmental Epileptic Encephalopathy, aiming to assess safety, tolerability, and efficacy. BMB-101, designed for chronic treatment, demonstrated safety and target engagement in Phase 1 studies.
Related Clinical Trials
Highlighted Terms
Related News
Bright Minds Biosciences initiates BREAKTHROUGH Study, a Phase 2 trial evaluating BMB-101, a selective 5-HT2C agonist, in adults with Absence Epilepsy and Developmental Epileptic Encephalopathy. The trial aims to assess safety, tolerability, and efficacy, with a planned open-label extension. Financial runway extends into 2026, supporting the study's completion.
Bright Minds Biosciences initiates Phase II BREAKTHROUGH trial of BMB-101, a 5-HT2C receptor agonist, for adults with classic absence epilepsy and developmental epileptic encephalopathy (DEE). The open-label basket trial aims to enrol 20 participants aged 18-65, assessing safety, tolerability, and effectiveness over a 12-week treatment phase, followed by a four-week follow-up. Primary efficacy endpoints include changes in generalised spike-wave discharges and seizure frequency.
Bright Minds Biosciences initiates Phase II BREAKTHROUGH trial of BMB-101, a 5-HT2C receptor agonist, for adults with absence epilepsy and developmental epileptic encephalopathy (DEE). The trial aims to assess safety, tolerability, and effectiveness over a 12-week treatment phase, followed by a four-week follow-up.
Bright Minds Biosciences initiates BREAKTHROUGH Study, a Phase 2 trial evaluating BMB-101, a 5-HT2C agonist, in adult patients with Absence Epilepsy and Developmental Epileptic Encephalopathy. The trial aims to assess safety, tolerability, and efficacy, with a planned open-label extension. Financial runway extends into 2026, supporting the study and future development.
Bright Minds Biosciences initiates phase 2 BREAKTHROUGH trial to assess BMB-101, a 5-HT2C receptor agonist, in adults with absence epilepsy and DEE. Centessa Pharmaceutical reports positive interim results from phase 1 trial of ORX750, an OX2R agonist for sleep disorders, advancing to phase 2 trials for narcolepsy and idiopathic hypersomnia. Dosing begins for phase 1 MAD trial of QRL-101, a Kv7.2/7.3 ion channel opener for ALS, with topline results expected in 2025.
Bright Minds Biosciences initiates BREAKTHROUGH Study, a Phase 2 trial evaluating BMB-101, a 5-HT2C agonist, for drug-resistant epilepsy. The trial targets 20 adult participants with Absence Epilepsy or Developmental Epileptic Encephalopathy, aiming to assess safety, tolerability, and efficacy. BMB-101, designed for chronic treatment, demonstrated safety and target engagement in Phase 1 studies.